Navigation Links
Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
Date:6/26/2009

DEERFIELD, Ill., June 26, and OSAKA, Japan, June 27, 2009 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") today announced that Takeda Global Research & Development Center, Inc., a wholly owned United States (U.S.) subsidiary received on June 26 (U.S. time) a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the Company's New Drug Application (NDA) for alogliptin, a selective dipeptidyl peptidase IV (DPP-4) inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise. In recent months, the FDA and Takeda have been in discussions about conducting an additional cardiovascular study for alogliptin.

As previously announced on March 6, 2009, the FDA informed Takeda that, although the alogliptin NDA was filed prior to the release of the December 2008 FDA Guidance titled, "Guidance for Industry: Diabetes Mellitus -- Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes," the FDA did not believe that the amount of existing alogliptin clinical data was sufficient to meet certain statistical requirements outlined in that Guidance. The FDA has asked Takeda to conduct an additional cardiovascular safety trial that satisfies the December 2008 FDA Guidance.

"Takeda will continue to promote key initiatives in order to realize sustained growth from a medium- to long-term perspective," said Takeda President & CEO, Yasuchika Hasegawa.

About Takeda Pharmaceutical Company Limited

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available through its co
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
2. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
3. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
4. Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
5. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
6. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
7. Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filings in Europe
8. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
9. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
10. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
11. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Sept. 2, 2014  Volcano Corporation (Nasdaq: ... improving patient and economic outcomes on a global ... coronary and peripheral visualization, physiology diagnostics and therapies, ... the Morgan Stanley Healthcare conference on Tuesday, September ... Huennekens , president and chief executive officer, will ...
(Date:9/2/2014)... 2014  VentiRx Pharmaceuticals, Inc., a clinical ... and commercialization of novel Toll-like receptor 8 ... corporate and clinical activities at the company ... ongoing clinical trials and future clinical development ... Executive Officer Robert Hershberg , M.D., ...
(Date:9/2/2014)... Sept. 2, 2014  VentiRx Pharmaceuticals, Inc., ... the development and commercialization of novel Toll-like ... the U.S. Food and Drug Administration (FDA) ... investigation of motolimod (VTX-2337) when administered in ... the treatment of women with ovarian cancer ...
Breaking Medicine Technology:VentiRx Pharmaceuticals Provides Corporate and Clinical Update 2VentiRx Pharmaceuticals Provides Corporate and Clinical Update 3VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer 2VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer 3
... May 20, 2011 Neuland Laboratories Ltd., (NSE:NEULANDLAB; BOM:524558) ... intermediates, and contract research and manufacturing services to customers ... the 2011 fiscal year (FY) ended March 31, 2011. ... in fiscal year 2011, Neuland delivered on our commitment ...
... Winner Medical Group Inc. (Nasdaq: WWIN ; ... medical dressings, medical disposables and non-woven fabric made from ... that its PurCotton Industrial Wipes was nominated one of ... Award™. The Company will compete with the ...
Cached Medicine Technology:Neuland Labs Reports Financial Results for Fiscal Year 2011 2Winner Industries (Shenzhen) Nominated for WOW Innovation Award(TM) 2Winner Industries (Shenzhen) Nominated for WOW Innovation Award(TM) 3Winner Industries (Shenzhen) Nominated for WOW Innovation Award(TM) 4
(Date:9/2/2014)... 2014 The global market for peripheral ... by 2020, growing at an estimated CAGR of 7.2% ... by Grand View Research, Inc. Peripheral vascular devices such ... are used for treating peripheral arterial or coronary arterial ... in arteries. These devices are used to decrease the ...
(Date:9/2/2014)... Eric Jimenez and Leah Ashley announced today ... makeup application device. Designed to improve and accelerate makeup ... palm of women’s hands to help them get flawless ... success lies in its patented technology. With a battery-operated ... pulses per minute, the device applies foundation evenly in ...
(Date:9/2/2014)... BESLER Consulting, a leading provider of ... pleased to announce that it has released a special ... FY 2015 Hospital Inpatient Prospective Payment System (IPPS) final ... Medicaid Services. , “Hospitals are facing decreased Medicare reimbursements ... Besler, BESLER’s President and Chief Executive Officer. “We are ...
(Date:9/2/2014)... 02, 2014 At the world-famous Magic Castle ... the unique distinction of being the first and only female ... Lee is the first female magician to hold such a ... at the Magic Castle,” says Misty Lee. “Even since I ... the Magic Castle, I can fascinate guests in much the ...
(Date:9/2/2014)... Request A Test , a leading national provider of direct to ... drug testing in September 2014. To take advantage of ... when placing their order. Request A Test offers a variety ... is typically done in panels which screen for multiple types of ... the 5 Panel Urine Screening and 10 Panel ...
Breaking Medicine News(10 mins):Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 2Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 3Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 4Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 5Health News:Color Me Launches With Ulta Beauty Revolutionary Makeup Application Device Gets Women Flawless in a Flash 2Health News:Color Me Launches With Ulta Beauty Revolutionary Makeup Application Device Gets Women Flawless in a Flash 3Health News:Magician Misty Lee is the First and Only Female Staff Medium at Hollywood’s Magic Castle 2Health News:Request A Test Offers 10% Off Drug Testing in September 2014 2Health News:Request A Test Offers 10% Off Drug Testing in September 2014 3
... are struggling with the health fallout caused by a lack ... Most women don,t need a survey to tell them a ... too sluggish to make it through the day with vigor. ... moms, empty-nesters or grandmothers, many -- if not most -- ...
... under 80, could ease expected worldwide shortfall of supplies , , ... called HBOC-201 proved safe and effective in a six-week Phase ... In all, 688 patients, ages 18 and older, who had ... (about one pint) or an equivalent one unit (65 grams) ...
... 20 The United States,has provided $50,000 in ... to assist people affected by the food,shortages in ... emerged in recent months because the flowering of ... rat infestations in,crop-growing areas. With funds provided by ...
... of,Agriculture is recommending that consumers who have purchased raw ... County, discard it immediately,due to the risk of Listeria ... milk is milk that has not been pasteurized or ... requires they obtain,permits and be inspected to reduce health ...
... Tenn., June 20 TeamHealth announced today,that Heidi S. ... counsel, reporting directly to the CEO. Ms. Allen is ... retire on July 31,2008, after nine years with TeamHealth., ... a member of TeamHealth,s senior,management team, working with all ...
... shows , , FRIDAY, June 20 (HealthDay News) -- Measles may ... world, but new research shows that it does not spread ... believed. , Mayo Clinic researchers, whose work was published ... of Clinical Investigation , reported that the measles virus instead ...
Cached Medicine News:Health News:So Much to Do, So Little Sleep 2Health News:So Much to Do, So Little Sleep 3Health News:Blood Substitute Found Safe in Large Phase III Trial 2Health News:PA Agriculture Department Warns Consumers About Raw Milk Sold by York County Dairy 2Health News:TeamHealth Announces Appointment of Heidi Allen as Senior Vice President and General Counsel 2Health News:Measle's Spread Doesn't Depend on Airways 2
Used in conjunction with the E5381 600 Circling Band (40 style). Indications: When high buckle is required. Overall length: 14.0 mm....
Concave inner surface to conform to the globe. Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Wide scleral bed. Outside diameter 30.2 mm....
...
...
Medicine Products: